Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 10/20 | 0.67 |
| ▸ | BCHE | P06276 | 6/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9547692 | 0.81 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2ACYP1A2 | |
| SCHEMBL9875466 | 0.79 | ACHE (0.67) | ACHEBCHECYP1A2CYP2C9TSHR | |
| SCHEMBL10286361 | 0.77 | ACHE (0.69) | ACHEBCHEGRIN1GRIN2ACHRM1 | |
| SCHEMBL10286854 | 0.76 | ACHE (0.50) | ACHEBCHEGRIN1GRIN2AALDH1A1 | |
| SCHEMBL10522714 | 0.75 | ACHE (1.00) | ACHEBCHEGRIN1GRIN2ACYP1A2 | |
| SCHEMBL10287364 | 0.73 | ACHE (0.47) | ACHEBCHEGRIN1GRIN2AALDH1A1 | |
| SCHEMBL10286861 | 0.71 | ACHE (0.50) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL10287399 | 0.70 | ACHE (0.49) | ACHEBCHEGRIN1GRIN2A | |
| SCHEMBL10287338 | 0.70 | ACHE (0.39) | ACHETSHRALDH1A1 | |
| SCHEMBL10286449 | 0.70 | ACHE (0.70) | ACHECYP1A2CYP2C9TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA CROP PROTECTION LLC (US) | 2013-04-25 | — | — | US | disclosed |
| WO-2012001040-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102631-A1 | NOVEL MICROBIOCIDAL DIOXIME ETHER DERIVATIVES | MSR1, DDT, MPO | ACHE 660/4885BCHE 2014/4885GRIN1 3414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.